Vaccine Design pp 119-127 | Cite as

Vaccines and Vaccine Delivery Systems: Experience with HSV, Influenza and Mucosal Routes of Immunisation

  • R. Jennings
  • D. Ní Challanáin
  • H. O. Ghazi
  • C. S. McLean
Chapter
Part of the NATO ASI Series book series (NSSA, volume 293)

Abstract

The primary route of entry into the body for many viruses, including herpes simplex virus type 2 (HSV-2) and the influenza virus, is via mucosal surfaces. It follows that, depending on the numbers of virions deposited on such surfaces, their infectious quality and distribution over the mucosal surface, the existence or early mobilisation of specific defence mechanisms at the time of this contact, supplementing or enhancing any non-specific resistance mechanisms already operating at these sites may tip the balance in favour of the host and result in elimination of the invading virus before it can become established in the tissues and produce disease symptoms.

Keywords

Influenza Virus Mucosal Surface Genital Herpes Influenza Virus Vaccine Vaccine Delivery System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asanuma, H., Koide, F., Suzuki, Y., Nagamine, T., Aizawa, C., Kurata, T and Tamura, S., 1995, Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine, 13, 3.PubMedCrossRefGoogle Scholar
  2. Barr, I.G. and Mitchell, G.F., 1996, ISCOMs (immunostimulating complexes): The first decade. Immunology and Cell Biology, 74, 8.PubMedCrossRefGoogle Scholar
  3. Ben-Ahmeida, E.T.S., Jennings, R., Erturk, M. and Potter, C.W., 1992, The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMs, with FCA, ALH or as infectious virus. Archives of Virology, 125, 71.PubMedCrossRefGoogle Scholar
  4. Ben-Ahmeida, E.T.S., Gregoriadis, G., Potter, C.W. and Jennings, R., 1993, Immuno-potentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine, 11, 1302.PubMedCrossRefGoogle Scholar
  5. Bowen, J.C., Alpar, H.O., Phillpotts, R. and Brown, M.R.W., 1992, Mucosal delivery of herpes simplex virus vaccine. Research in Virology, 143, 269.PubMedCrossRefGoogle Scholar
  6. Byars, N.E., Fraser-Smith, E.B., Pecyk, R.A., 1994, Vaccinating guinea-pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine, 12, 200.PubMedCrossRefGoogle Scholar
  7. de Haan, A., Renegar, K.B., Small, P.A. Jr. and Wilschutt, J., 1995, Induction of a secretory IgA response in the murine female urogenital tract by immunisation of the lungs with liposome-supplemented viral subunit antigen. Vaccine, 13, 613.PubMedCrossRefGoogle Scholar
  8. Eis-Hubinger, A.M., Schmidt, D.S. and Schneweis, K.E., 1993, Anti-glycoprotein B mono-clonal antibody protects T-cell depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. Journal of General Virology, 74, 379–385.PubMedCrossRefGoogle Scholar
  9. Erturk, M., Jennings, R., Hockley, D. and Potter, C.W., 1989, Antibody responses and protection in mice immunised with herpes simplex type 1 antigen immune-stimulating complex preparations. Journal of General Virology, 70, 2149.PubMedCrossRefGoogle Scholar
  10. Erturk, M., Jennings, R., Philipotts, R.J. and Potter, C.W., 1991, Biochemical characterisation of herpes simplex type 1 immunostimulating complexes (ISCOMs): A multiglyco-protein structure. Vaccine, 9, 668.PubMedCrossRefGoogle Scholar
  11. Erturk, M., Philipotts, R.J. Welch, M.J. and Jennings, R., 1991, Efficacy of HSV-ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine, 9, 728.PubMedCrossRefGoogle Scholar
  12. Erturk, M., Hill, T.J., Shimeld, C. and Jennings, R., 1992, Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine. Archives of Virology, 125, 87.PubMedCrossRefGoogle Scholar
  13. Farag, I.F., Phili, R.W., Rosborough, J.P. and Six, H.R., 1988, Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine, 6, 262.CrossRefGoogle Scholar
  14. Farrell, H., McLean, C.S., Harley, C., Efstathiou, S., Inglis, S.C. and Minson, A.C., 1994, Vaccine potential of a herpes simplex virus type 1 mutant with an essential glyco-protein deleted. Journal of Virology, 68, 927.PubMedGoogle Scholar
  15. Galuchan, W.S. and Rosenthal, K.L., 1995, Specific secretory immune responses in the female genital tract following intranasal immunisation with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine, 13, 1589.CrossRefGoogle Scholar
  16. Gallichan, W.S. and Rosenthal, K.L., 1996, Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunisation. Journal of Experimental Medicine, 184, 1879.PubMedCrossRefGoogle Scholar
  17. Ghazi, H.O., Potter, C.W., Smith, T.L. and Jennings, R., 1995a, Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. Journal of Medical Microbiology, 42, 53.PubMedCrossRefGoogle Scholar
  18. Ghazi, H.O., Erturk, M., Stannard, L.M., Faulkner, M., Potter, C.W. and Jennings, R., 1995b, Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice. Archives of Virology, 140, 1015.PubMedCrossRefGoogle Scholar
  19. Hassan, Y., Brewer, J.M., Alexander, J. and Jennings, R., 1996, Immune responses in mice induced by HSV-1 glycoprotein presented with ISCOMs or NISV delivery systems. Vaccine, In press.Google Scholar
  20. Hazama, M., Mayumi-Aono, A., Miyazaki, T., Hinuma, S. and Fujisawa, Y., 1993, Intranasal immunisation against herpes simplex virus infection by using a recombinant glyco-protein D fused with immuno-modulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology, 78, 643.PubMedGoogle Scholar
  21. Jones, P.D., Tha-Hla, R., Morein, B., Lovgren, K. and Ada, G.L., 1988, Cellular immune responses in the murine lung to local immunisation with influenza A virus glyco-proteins in micelles and immuno-stimulatory complexes. Scandinavian Journal of Immunology, 27, 645.PubMedCrossRefGoogle Scholar
  22. McBride, B.W., Ridgeway, P., Philipotts, R. and Newell, D.G., 1988, Mucosal antibody response to vaginal infection with herpes simplex virus in pre-vaccinated guinea-pigs. Vaccine, 6, 414.PubMedCrossRefGoogle Scholar
  23. McDermott, M.R., Brais, L.J and Evelegh, M.J., 1990, Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. Journal of General Virology, 71, 1497.PubMedCrossRefGoogle Scholar
  24. McGhee, J.R. and Kiyono, H., 1993, New perspectives in vaccine development: Mucosal immunity to infections. Infectious Agents and Disease, 2, 55.PubMedGoogle Scholar
  25. McLean, C.S., Erturk, M., Jennings, R., Ni Challanain, D., Minson, A.C., Duncan, I. Bournsell, M.E.G. and Inglis, S.C., 1994, Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. Journal of Infectious Diseases, 170, 100.CrossRefGoogle Scholar
  26. McLean, C.S., Ni Challanain, D., Duncan, I., Bournsell, M.E.G., Jennings, R. and Inglis, S.C., 1996, Induction of a protective immune response by mucosal immunisation with a DISC HSV-1 vaccine. Vaccine, 14, 987.PubMedCrossRefGoogle Scholar
  27. Meitin, C.A., Bender, B.S. and Small, P.A. Jr., 1991, Influenza immunisation: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine, 9, 751.PubMedCrossRefGoogle Scholar
  28. Moldoveanu, Z., Novak, M., Huang, W-Q, Gilley, R.M., Staas, J.K., Schafer, D., Compans, R.W. and Mestecky, J., 1993, Oral immunisation with influenza virus in biodegradable microspheres. Journal of Infectious Diseases, 167, 84.PubMedCrossRefGoogle Scholar
  29. Moldoveanu, Z., Clements, M.L., Prince, S.J., Murphy, B.R. and Mestecky, J., 1995, Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine, 13, 1006.PubMedCrossRefGoogle Scholar
  30. Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K. and Osterhaus, A., 1984, ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308, 457.PubMedCrossRefGoogle Scholar
  31. Mowat, A. McI., 1987, The regulation of immune responses to dietary protein antigens. Immunology Today. 8, 93.CrossRefGoogle Scholar
  32. Mowat, A.McI., Donachie, A.M., Reid, G. and Jarrett, O., 1991, Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology, 72, 317.PubMedGoogle Scholar
  33. Mowat, A.McI., Maloy, K.J. and Donachie, A.M., 1993, Immune stimulating complexes (ISCOMs) are unique adjuvants for oral immunisation with protein antigens. Immunology, 80, 661.Google Scholar
  34. Offit, P.A. and Dudzik, K.I., 1989, Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. Journal of Virology, 63, 3507.PubMedGoogle Scholar
  35. Pang, G.T., Clancy, R.L., O’Reilly, S.E. and Cripps, A.W., 1992, A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunisation. Journal of Virology, 66, 1162.PubMedGoogle Scholar
  36. Renegar, K.B. and Small, P.A. Jr., 1991, Passive transfer of local immunity to influenza virus infections by IgA antibody. Journal of Immunology, 146, 1972.Google Scholar
  37. Roitt, I., Brostoff, J. and Male, D., eds., 1996, Vaccination, In: “Immunology”, Chapter 19; p. 191. 4th Edition, Published by Mosby.Google Scholar
  38. Thapar, M.A., Parr, E.L. and Parr, M.B., 1990, The effect of adjuvants on antibody titres in mouse vaginal fluid after intravaginal immunisation. Journal of Reproductive Immunology, 17, 207.PubMedCrossRefGoogle Scholar
  39. Thornton, B., Baskerville, A., Bailey, N.E., Melling, J.M. and Hambleton, P., 1984, Herpes simplex virus genital infection of the female guinea-pig as a model for evaluation of an experimental vaccine. Vaccine, 2, 141.PubMedCrossRefGoogle Scholar
  40. Walker, R.L., 1994, New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine, 12, 387.PubMedCrossRefGoogle Scholar
  41. Whaley, K.J., Zeitlin, L., Barratt, R.A., Hoen, T.E. and Cone, R.A., 1994, Passive immunisation of the vagina protects mice against vaginal transmission of genital herpes infections. Journal of Infectious Diseases, 169, 647.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • R. Jennings
    • 1
  • D. Ní Challanáin
    • 1
  • H. O. Ghazi
    • 1
  • C. S. McLean
    • 2
  1. 1.Department of Medical MicrobiologyUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Cantab Pharmaceuticals Research Ltd.CambridgeUK

Personalised recommendations